Milestone Pharmaceuticals Inc.
MIST · XNASCIK 1408443fmd_10ZM3G34KFDNHY33VQWK5RC8NHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 35 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 17 | 42 | 34 | 39 | 40 | 31 | 14 | 18 |
| Operating income | (24) | (58) | (51) | (43) | (60) | (61) | (42) | (62) |
| Interest expense | – | – | – | – | – | 3 | 4 | 4 |
| Interest and investment income | – | – | – | – | – | 4 | 4 | 3 |
| Income before taxes | (23) | (55) | (50) | (43) | (58) | (60) | (42) | (63) |
| Income tax expense | 0 | (0) | (0) | – | – | – | – | – |
| Net income from continuing operations | (23) | (55) | (50) | – | – | – | – | – |
| Net income | (23) | (55) | (50) | (43) | (58) | (60) | (42) | (63) |